Necrolytic migratory erythema, first symptom of a malignant glucagonoma: Treatment by long-acting somatostatin and surgical resection. Report of three cases

European Journal of Surgical Oncology

Volumn 24, Issue 6, 1998, Pages 562-567

  Rassi, Z El ^a   Partensky, C ^a   Valette, P J ^a   Berger, F ^a   Chayvialle, J A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Glucagonoma; Necrolytic migratory erythema; Somatostatin; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCAGON; SOMATOSTATIN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURGERY; CASE REPORT; ERYTHEMA; FEMALE; GLUCAGONOMA; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031650318     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0748-7983(98)93716-7     Document Type: Article

References (56)

1. Le Bobic MF, Heymann MF, Lecomle M, et al. Immunohislochemical study of 100 pancreatic tumours in 28 patients with multiple endocrine neoplasia. type I. Am J Surg Pathol 1996; 20(11): 1378-84.
2. Thompson NW, Eckhausser FE. Malignant islet cell tumors of the pancreas. World J Surg 1984; 8: 1-12.
3. Higgins GA, Recant L, Fischman AB. The glucagonoma syndrome. Am J Surg 1979; 137: 162-8.
4. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphiol 1942; 45: 1069-75.
5. McGavran MH, Unget RH, Recant L, Polk HC, Kilo C, Levin ME. A glucagon-secreting alpha cell carcinoma of the pancreas. N Engt J Med 1966; 274: 1408-13.
6. Mallinson CN, Bloom SR, Warin AP, et al. A glucagonoma syndrome. Lancet 1974; 2: 1-5.
7. Leichter SB. Clinical and metabolic aspects of glucagonoma. Meet Baltimore 1980; 59(2): 100-13.
8. Grant CS. Surgical management of malignant islet cell tumors. World J Surg 1993; 17:498-503.
9. Bloom SR, Polak JM. Glucagonoma syndrome. Am J Med 1987; 82: 25-36.
10. Clouse ME, Perry L, Stuart K., Stokes K.R. Hepatic arterial chemoembolizalion for melastalic ncuroendocrine tumors. Digestion 1994; 55 (Suppl. 3): 92-7.
11. Werners RA. Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Med Baltimore 1996; 75(2): 53-63.
12. Maillard H, Celerier P, Maisonneuve C. et al. Necrolytic migratory erythema without glucagonoma. Ann Dermatol Venerol 1995: 122(11-12): 786-8.
13. Marinkovich M P. Bolella R, Datloff J. Sangueza OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol 1995; 32(4): 604-9.
14. Binnick AN. Spencer SK. Dennison WL. Horion ES. Glucagonoma syndrome. Arch Dermatol 1977; 113: 749.
15. Kahan RS, Perez-Figaredo RA, Neimanis A. Necrolytic migratory erythema. Arch Dermatol 1977; 113: 792.
16. Roggli VL. Judge DM, McGavran MH. Duodenal glucagonoma: a case report. Hum Pathol 1979; 10: 350-3.
17. Gleeson MH, Bloom SR. Polak JM, et al. Endocrine tumor in the kidney affecting small bowel structure, mobility, and absorptive function. Gut 1971: 12: 773-82.
18. Guillausseau PJ, Guillausseau-Scholer C, Villet R, Kaloustian E, et al. Les glucaginomes. Aspects cliniques, biologiques, analomopathologiques el thérapeulhiques: revue generale de 130 cas. Gastroenterol Clin Biol 1982; 6: 1029-41.
19. Long RG. Barnes AJ. Adrian TE. et al. Suppression of pancreatic endocrine tumor secretion by long acting somatostatin analogue. Lancet 1979; 2: 764-7.
20. Vance JE, Stoll RW. Kitabchi AE, Williams RH, Wood FC. Nesidioblastosis in familial endocrine adenomatosis. JAMA 1969; 207: 1679-82.
21. Croughs RJM, Hulsmans HAM. Schopman W, et al. Glucagonoma as part of the polyglandular adenoma syndrome. Am J Med 1972; 52: 690-8.
22. Guillausseau PJ. Guillausseau-Scholer C. Glucagonomas: clinical presentation, diagnosis, and advances in management. Castrointest Res 1995; 23: 183-93.
23. Warner T. Block M, Bloom S. Glucagonomas: ultrastructure and immunocytochemistry. Cancer 1983; 51: 1091-6.
24. Delcore R. Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994; 178: 187-211.
25. Edney JA. Hofmann S. Thompson JS, Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entily. Am J Surg 1990; 160: 625-9.
26. Udelsman R. Yeo CJ, Cameron JL, et al. Pancrealicoduodenectomy for selected pancreatic endocrine tumors. Surg Gynecol Obstet 1993; 177: 269-78.
27. Molin IM. Endocrine tumors of the pancreas. Surg Gynecol Obstet 1979; 149: 751-69.
28. Prinz RA, Badrinth K, Bunerji M, et al. Operative and chemolherapeutic management of malignanl glucagon producing tumors. Surgery 1981; 90: 713-9.
29. Prinz RA, Dorsh TR, Lawrence AM, et al. Clinical aspects of glucagon-producing islet cell tumors. Am J Gastrenterol 1981; 76: 125-31.
30. Grama D, Eriksson B. Akerslrom G, et al. Clinical characlerislics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16:632-92.
31. Smith AP. Stare DA. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol 1996; 61: 306-9.
32. Legaspi A, Brennan MF. Management of islet cell carcinoma. Surgery 1988; 104: 1018-23.
33. Thompson GB, van Heerden JA, Grant CS, et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988; 104: 1011-7.
34. Monenegro F, Lawrence GD, Macon G. Pass C. Metaslatic glucagonoma: improvement after surgical debulking. Am J Surg 1990; 139:424-7.
35. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091.
36. Friesen SR. Tumors of the endocrine pancreas. N Engl J Med 1982; 306: 580-90.
37. Kessinger A. Foley JF, Lemon HM. Therapy of malignant APUD cell tumors: effectiveness of DTIC. Cancer 1983; 51: 790-4.
38. Boden G, Ryan I, Eisenschmid BL, et al. Treatment of inoperable glucagonoma with long acting somatostatin analogue SMS 201 995. N Engl J Med 1986; 314: 1686-9.
39. Ajani JA. Carrasco CH. Wallace S. et al. Islet cell tumors metaslatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988: 108: 340-4.
40. Moertel CG, Hanley JA. Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 89-94.
41. Kvols LK. Buck M, Moertel CG, et al. Treatment of islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987: 107: 162-8.
42. Friesen SR. Tumors of the endocrine pancreas. N Engl J Med 1982:306: 580-90.
43. Alitamari AF. Badrinath K. Reisel HJ. Prinz RA. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 1987: 102(6): 1009-17.
44. Friesen SR. Update on the diagnosis and treatment of. rare neuroendocrine tumors. Surg Clin North Am 1987; 67(2): 379-93.
45. Van der Loos TL. Lambercht ER. Lambers JC. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol 1987; 16: 468-72.
46. Modlin IM, Lewis JJ. Ahlman H. et al. Management of unresectable malienant tumors of the pancreas. Surg Gynecol Obstet 1993; 176: 507-18.
47. Vinik AI, Tsai ST, Moattari AR, et al. Somalostatin analogue SMS 201-995 in the management of gastroenteropancreatic tumors and diarrhea syndrome. Am J Med 1986; 81: 23-40.
48. Eriksson B, Teinsuu Janson E, Bax NDS. Mignon M. The use of new sandostatin analogues, Lantreolide and Octastatin, in neuroendocrine gastrointestinal tumors. Digestion 1996; 57 (Suppl. 1): 77-80.
49. Lamberts SWJ, Van Der Lely A-J, De Herder WW. Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-53.
50. Altimari AF, Bhoopalam N, O'Dorsio T, et al. Use of a somatostatin analogue (SMS 201-995) in the gluconoma syndrome. Surgery 1986: 100(6): 989-96.
51. Souquet JC, Sassolas G, Partensky C. et al. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987:59(9): 1654-60.
52. Debas HT, Gittes G. Somalostatin analogue therapy in functioning neuroendocrine gut tumors. Digestion 1993; 54 (Suppl. 1): 68-71.
53. Friemann J, Padur R. Hepatic arterial embolization for trealmenl of glucagonomas: antineoplasic and palliative benefits. Am J Clin Oncol 1990; 13(3): 2271-5.
54. Moerlel CG, Johnson CM, McKuscick MA, et al. The management of patients with advanced carcinoid lumors and islet cell carcinomas. Ann Intern Med 1994; 120: 302-9.
55. Debas HT, Mulvihill SJ. Neuroendocrine gut neoplasms: important lessons from uncommon tumors. Arch Surg 1994; 129: 965-72.
56. Anthuber M, Jauch KW, Briegel J, et al. Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 1996; 20(1): 73-6.